Gilead Sciences (GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $127.88 +3.26%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- Popular stocks with increasing option volume: MU MSTR SPCX PLTR NFLX INTC NOK SOFI HOOD BABA
- Increasing unusual put volume: AS WEN REPL BHC BTG IGV HWM CHYM BURL CIA
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
